Co-Authors
This is a "connection" page, showing publications co-authored by NAVAL DAVER and JAMES P ALLISON.
Connection Strength
0.998
-
Checkpoint Blockade + Chemotherapy: the Right Combination for AML? Blood Cancer Discov. 2021 Nov; 2(6):551-554.
Score: 0.203
-
The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. 2019 05 01; 125(9):1470-1481.
Score: 0.167
-
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Cancer Discov. 2019 03; 9(3):370-383.
Score: 0.166
-
Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Leukemia. 2018 05; 32(5):1094-1105.
Score: 0.159
-
The emerging role of immune checkpoint based approaches in AML and MDS. Leuk Lymphoma. 2018 04; 59(4):790-802.
Score: 0.152
-
A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL. Blood Adv. 2023 05 23; 7(10):1958-1966.
Score: 0.057
-
Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. Nat Commun. 2021 10 18; 12(1):6071.
Score: 0.051
-
Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematol. 2019 Sep; 6(9):e480-e488.
Score: 0.044